AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01220739 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Laser Therapy
Description: Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.
Study NCT03741504 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforations (MOPs)
Description: three (3) micro-osteoperforations (MOPs) in the cortical and medullar bone, distal to the upper canine. These MOPs will be at the apical, medial and gingival zone of the bone located at the distal surface of the canine in the buccal and in the palatal side. The deep of the MOPs will be at 6 mm. It is going to be done with a PROPEL
Study NCT03859271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing
Description: Children and parents will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
Study NCT03859271 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
Study NCT00268840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50 mg/m2 ou 35 mg/m² (suivant le bilan hépatique) à J1 et J15 toutes les 4 semaines
Study NCT00268840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1200 mg/m2 à J1 et J15 toutes les 4 semaines
Study NCT05193162 — intervention group
Intervention type: OTHER
Intervention: No any intervention
Description: have no any intervention
Study NCT02911675 — intervention group
Intervention type: DEVICE
Intervention: EVD/IVC and the IPM/Camino
Description: This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
Study NCT01470391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor-Canal-Blockade
Description: US-guided Adductor-Canal-Blockade with Ropivacaine
Study NCT01470391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: US-guided Femoral Nerve Block with Ropivacaine
Study NCT01153581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix acetate
Description: Ganirelix acetate: .25 ml/day by subcutaneous injection
Study NCT01153581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17β-Oestradiol
Description: 17 beta estradiol: 0.2 mg/day (patches)
Study NCT01153581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: progesterone, 200 mg day-1 oral
Study NCT00181766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Strattera (atomoxetine)
Description: Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).
Study NCT01664182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01664182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01664182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT03765294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Film-coated tablet for oral use
Study NCT03765294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet for oral use
Study NCT01556204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Description: The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
Study NCT01556204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery
Description: The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
Study NCT02456324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICS-AF Device
Description: This is a specialized closure system for anorectal fistulas that is sphincter sparing
Study NCT01664182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT01664182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Given IV
Study NCT05069376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteral Stent of 5-22 or 5-24
Description: Boston Scientific Polaris™ Ultra Ureteral Stent
Study NCT00515879 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT sessions aim to help participants become more comfortable with social situations.
Study NCT04496856 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein and Collagen supplementation
Description: Participants of each arm will consume 30 g daily of the assigned protein supplementation for 30 days. The protein supplementation will be given as protein powder which the participants will have to dissolve in cold drinks. During the intervention fat free mass, muscle strength, functional ability, wound healing and life quality of the participants will be monitored.
Study NCT02919046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
Study NCT02036125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.
Study NCT02036125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Subjects will receive a blind injection of 40 mg of methylprednisolone.
Study NCT02036125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Subjects will receive a blind injection of 40 mg of methylprednisolone.
Study NCT02456324 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Historical Controls Treated with Commercially Available Fistula Plugs
Description: These are patients previously treated with commercially available fistula plugs.
Study NCT00515879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same dosage as active pill
Study NCT03836768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRMWXHS-12
Description: DTRMWXHS-12 capsules: 150 mg, 300 mg
Study NCT01880658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
Study NCT04293185 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: bb1111
Description: Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
Study NCT03728543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection
Study NCT03728543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection
Study NCT03959059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mixed Reality technology
Description: combine image with real body
Study NCT03168412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
Study NCT03856502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 mg of dexamethasone
Description: Effect of intrathecally administered dexamethasone in spinal anaesthesia for surgical correction of the hip fracture.
Study NCT03856502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12,5 mg of 0,5 % of levobupivacaine
Description: Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.
Study NCT03856502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12,5 mg of 0,5 % of levobupivacaine
Description: Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.
Study NCT03168412 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Description: Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
Study NCT00508326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose 150 mg/m\^2 HAI once every 4 weeks
Study NCT03189394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIDE
Description: A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
Study NCT03189394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePRIDE
Description: A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
Study NCT03189394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Men's Health
Description: A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
Study NCT00298831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.
Study NCT00298831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
Study NCT00688766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retaspimycin hydrochloride (IPI-504)
Description: IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
Study NCT00688766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
Study NCT00688766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
Study NCT00688766 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
Study NCT04419116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tibial preservation bone cut
Description: tibial preservation bone cut: removing of proximal tibial less than conventional tibial bone cut with 2mm.
Study NCT04587193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assist gait training device
Description: PD participants will walk while wearing a robotic-assist gait training device
Study NCT01720069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VR506
Description: VR506 inhalation powder delivered via a new dry powder inhaler device
Study NCT03707288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spine Exercise Program
Description: Spine exercises should be done 20 minutes/ 3 days per week Desk stretches should be done when exposed to prolonged sitting for greater than 60 mins
Study NCT04615559 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound
Description: CEUS involves the use of microbubble contrast agents and specialized imaging techniques to enhance the signal from blood, thus showing flow in macroscopic vessels as well as tissue perfusion information
Study NCT04069208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin and cytarabine induction
Description: Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
Study NCT00379470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NovoTTF-100A
Description: multiple four-week courses of continuous NovoTTF-100A treatment
Study NCT00379470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A
Description: multiple four-week courses of continuous NovoTTF-100A treatment
Study NCT03676361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Subjects will complete a water deprivation test using desmopressin to aid in the determination of maximum tubular concentration capacity before and six months after uni-nephrectomy.
Study NCT00411619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
Study NCT03591575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone oral solution
Description: Liquid formulation of deferiprone, with a concentration of 80 mg/mL
Study NCT03591575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid solution that matches deferiprone oral solution in appearance and taste
Study NCT02265393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02120638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide containing regimen
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, >70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, >70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, >50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
Study NCT01521507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow System
Description: In-office device treatment for meibomian gland dysfunction by a physician
Study NCT01521507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow System
Description: In-office device treatment for meibomian gland dysfunction by a physician
Study NCT03692767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD22 CAR NK Cells
Description: Anti-CD22 CAR NK Cells injection
Study NCT02469402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Study NCT02469402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin
Study NCT02120638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regimen without Pyrazinamide
Description: Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, >70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, >50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, >70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.
Study NCT04045769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 4mg
Description: 1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally
Study NCT04045769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 5 tablets of placebo to be administered orally
Study NCT04045769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: 1 tablet of 400 mg Moxifloxacin to be administered orally
Study NCT04045769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 20 mg
Description: 5 tablets of 4 mg Saroglitazar magnesium to be administered orally
Study NCT00595621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)
Description: Multi-Channel Phased Gastric Pacemaker (MGP-1)
Study NCT03412721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser analgesic procedure
Description: Water mist spray set to maximum, non-contact handpiece with sapphire tip. Tip-to-tissue distance 10 mm from the tooth neck, achieved by using a spacer. Energy is delivered to the enamel above the gingival margin adjacent to the cemento-enamel junction (perpendicularly towards the dental pulp) on each of the four line angles of the tooth for 30s, moving the laser handpiece in a sweeping action. Pulse energy - 0.2 W/ 10 Hz/ 20 mJ. Follows increase of energy and repetition of protocol - 0.6 W/ 15 Hz/ 40 mJ. Total duration of LA-induction - 240s.
Study NCT03412721 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo analgesic procedure
Description: Performing imitation of laser analgesic procedure. No pulse energy applied, non-contact handpiece with sapphire tip. Moving the laser handpiece in a sweeping action towards the cemento-enamel junction (pointing perpendicularly towards the dental pulp) on each of the four line angles of the tooth. Total duration of placebo analgesia induction - 240s.